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EVALUATING PROTEASOME MODULATION AS A THERAPEUTIC 
STRATEGY IN NEMALINE MYOPATHY 
JEFFREY WANG 
 
ABSTRACT 
 Nemaline myopathy is a subtype of congenital myopathy that is clinically 
characterized by muscle weakness and early hypotonia of variable severity. 
Pathologically, nemaline myopathy is characterized by the presence of nemaline rods that 
stain purple in modified Gӧmӧri trichrome dye in patient biopsies under a microscope. 
Affected individuals experience skeletal muscle weakness and feeding difficulties, but 
most individuals will also experience respiratory muscle weakness that is disproportional 
to the weakness in skeletal muscles. Currently, 6 different subtypes of nemaline 
myopathy have been identified, each caused by mutations in ACTA1, NEB, TPM2, TPM3, 
TNNT1, KBTBD13, CFL2, KLHL40, KLHL41, or LMOD3, which are genes that encode 
either thin filament proteins or Kelch-like proteins. Of these genes, mutations in NEB and 
ACTA1 account for the majority of nemaline myopathy cases. Due to the genetic 
heterogeneity of nemaline myopathy, it is imperative to discover therapeutic targets and 
treatments that can universally treat nemaline myopathy patients.  
 Preliminary data from our lab has demonstrated that proteasome complexes are 
downregulated in nemaline myopathy patients. Further, proteasomal activators improved 
motor function in neb zebrafish models, demonstrating the potential for proteasome 
activators to be therapeutics for nemaline myopathy patients. To extend these studies, the 
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effect of proteasome activators, betulinic acid and Rolipram, was evaluated on the motor 
function in neb zebrafish models. However, in our experimental trials with betulinic acid 
and Rolipram, no positive effect on motor function in neb zebrafish was observed. In 
order to confirm our findings for both betulinic acid and Rolipram, additional trials will 
need to be conducted. 
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INTRODUCTION 
Congenital Myopathies 
 Congenital myopathies are a group of inherited muscular disorders present at birth 
and are clinically characterized by muscle weakness, hypotonia, feeding difficulties and a 
delay in motor developmental milestones. Respiratory insufficiency is often associated 
with severe form of the disease (Sewry, 2008). Congenital myopathy patients have 
normal or mildly increased levels of serum creatine kinase compared with the elevated 
levels seen in muscular dystrophy patients. This is because congenital myopathy is not 
associated with necrosis or fiber regeneration in skeletal muscles. 
Different subtypes of congenital myopathies are classified by structural defects 
seen in muscle biopsies including nemaline rods, cores, central nuclei and fiber-type 
disproportion. These subtypes include nemaline myopathy, centronuclear myopathy, 
central core disease, multi-minicore disease, congenital fiber-type disproportion 
myopathy, and hyaline body myopathy  Congenital Myopathy Information Page, n.d.).  
Congenital myopathy is caused by mutations in different genes; however, a mutation in 
the same gene may result in different muscle pathologies in different patients. However, 
due to the genetic heterogeneity and clinical overlap of these subtypes, determining the 
underlying genetic cause of the pathology requires a multidisciplinary approach for 
proper diagnosis (Sewry & Wallgren-Pettersson, 2016). 
 Currently, an effective treatment utilizing a selective beta-adrenergic agonist, 
albuterol, exists only for core myopathy (Schreuder et al., 2010); however, no cure for 
congenital myopathy is available yet. Existing therapies are aimed at improving the 
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quality of life and alleviating the disease symptoms, including difficulties with breathing, 
feeding, speech and mobility; but do not address the underlying mechanisms or causes of 
these disorders (National Institute of Neurological Disorders and Stroke, n.d.). 
 
Nemaline Myopathy 
 Nemaline myopathy is a subtype of congenital myopathy that is characterized by 
the presence of nemaline rods in patient muscle fibers. The clinical spectrum for 
nemaline myopathy ranges widely from mild to severe. Six different subtypes of the 
disorder have been clinically defined depending on the age of onset and the severity of 
muscle weakness, which include typical congenital, intermediate congenital, severe 
congenital, mild childhood, adult onset, and Amish onset (Yin et al., 2014). Clinical 
symptoms of nemaline myopathy usually include axial, facial, and proximal limb muscle 
weakness, but arthrogryposis, a condition characterized by the fixation of a joint in an 
extended or flexed position, may occur in severe cases of nemaline myopathy (Sewry, 
2008). Respiratory distress  is often associated with nemaline myopathy and is the 
primary cause of death in the severe forms (Yin et al., 2014). Cardiac muscle 
involvement is extremely rare and has been identified in only one patient (Marseglia et 
al., 2015). 
 The most definitive characteristic of nemaline myopathy is the presence of 
nemaline rods in patient muscle biopsies, which stain purple with modified Gӧmӧri 
trichrome dye and can be viewed under a light microscope (Figure 1). Under an electron 
microscope, these nemaline rods are seen as electron dense rod-like or ovoid structures 
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(Figure 2) (Yin et al., 2014). Studies have shown that the main constituent of nemaline 
rods is α-actinin, a z-line protein (Sewry, 2008). These nemaline rods are distributed 
variably and are commonly subsarcolemmal or cytoplasmic in localization.  However, 
intranuclear  nemaline bodies have also been identified (North et al., 2014). The number 
of nemaline bodies in a patient’s biopsy does not correlate with clinical severity of 
symptoms (Malfatti et al., 2014). In some rare cases, Nemaline rods may be absent in 
muscle biopsies, despite having the mutation for nemaline myopathy (Sewry & Wallgren-
Pettersson, 2016).  
Clinical studies have suggested that these morphological defects are more 
prominent in type I muscle fibers (slow) than in type II (fast) muscle fibers. Within the 
muscle of affected individuals, type I muscle fiber predominance is often observed, but 
not universally observed in nemaline myopathy patients (Malfatti et al., 2014).  Variation 
in muscle fiber size and type I atrophy is also common in nemaline myopathy patients, 
but not universal. Type II muscle fiber hypertrophy may be observed as well, but may not 
be present in every affected individual (Sewry, 2008).  
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Figure 1: Gӧmӧri Trichrome Staining of a Nemaline Myopathy Patient Biopsy. Nemaline 
rods are stained purple in Gӧmӧri trichrome staining and are seen in multiple muscle fibers in the 
patient biopsy. (Sarullo et al., 2015) 
 
 
Figure 2: Electron Microscopy of a Nemaline Myopathy Patient Biopsy. Nemaline rods 
(arrows) are seen as electron-dense rods and ovoid structures. (Skram, Gulati, Larsson, Lindal, & 
Torp, 2009) 
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Studies have identified ten different genes as the cause of nemaline myopathy, 
including ACTA1, NEB, TPM2, TPM3, TNNT1, KBTBD13, CFL2, KLHL40, KLHL41, 
and LMOD3, which encode proteins of thin filaments or Kelch-like proteins. ACTA1, 
TPM2, and TPM3 mutations are inherited as autosomal dominant or autosomal recessive 
traits, KBTBD13 mutations are inherited only as autosomal dominant traits, while the 
remaining six genes are inherited as autosomal recessive traits (Malfatti et al., 2014). 
ACTA1, the second most common mutation in nemaline myopathy patients, accounts for 
approximately 20-25% of all cases, while NEB, being the most common mutation that 
occurs in nemaline myopathy patients, accounts for 40-50% of all nemaline myopathy 
cases. (North et al., 2014). 
NEB mutations are inherited as autosomal recessive traits. Carriers of the 
mutation do not express any disease phenotypes. Studies with mouse models have 
suggested that one wild-type allele can produce a sufficient amount of nebulin to assist in 
actin filament stabilization and myofribril organization (Chu, Gregorio, & Pappas, 2016). 
In these mouse models, the force generated by skeletal muscle contraction is similar to 
that in wild type mice skeletal muscles (Gineste et al., 2013). In contrast, Neb conditional 
knockout mice displayed a reduction in skeletal muscle force generation, which is 
believed to be a result of shorter thin filament length and a reduced fraction of force-
generating cross-bridges (Li et al., 2015). Other nebulin-deficient mouse (Bang et al., 
2006) and zebrafish (Telfer et al., 2012) models of nemaline myopathy have been 
generated and characterized with features similar to nemaline myopathy patients, 
including muscle weakness, reduced thin filament length, presence of nemaline rods, and 
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impaired muscle force generation. By sharing the main features with human nemaline 
myopathy patients, these models are ideally suited for discovery of potential therapeutics 
for the disease.  
 
Functional Role of Nebulin in Skeletal Muscles 
 Nebulin is a ~800kDa protein consisting of 183 exons, 17 of which have been 
shown to be alternatively spliced, which would result in different isoforms of nebulin in 
skeletal muscles (Pelin & Wallgren-Pettersson, 2008). Nebulin plays multiple functions 
in skeletal muscles including Z-disc assembly, myofibril organization and muscle 
contraction (Chu, Gregorio, & Pappas, 2016). In mature skeletal muscles, the N terminus 
of nebulin is located near the pointed end of the thin filament and has a high affinity for 
tropomodulin (Tmod), a thin filament capping protein. This transient interaction between 
nebulin and Tmod, assists in the proper assembly of actin filaments in myofibrils. On the 
other hand, the C terminus of nebulin is anchored to  Z-disc, interacts with CapZ and 
assists in a variety of processes including signaling, force generation, sarcomeric integrity 
maintenance, and myofibril assembly (Chu, Gregorio, & Pappas, 2016).  
 The nebulin protein has 185 tandem repeats of ~35 amino acids α-helical 
domains, each weakly interacting with an actin monomer. Many of the repeats are further 
grouped in 7-domain super repeats, which interact with the troponin and tropomyosin 
complex (Chandra et al., 2009). Because this region makes up approximately 90% of the 
protein, it is suggested that this region is important to its function as a stabilizer of actin 
filaments (Labeit, Ottenheijm, & Granzier, 2011). Studies have shown that nebulin may 
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be involved in a ‘two-segment model’ that Gokhin and Fowler suggested, which proposes 
that nebulin determines the minimal length of thin filaments (Gokhin & Fowler, 2013). 
Previous studies that explored the functionality of a mini-nebulin supported this model 
and provided evidence that nebulin does not behave like a molecular ruler for thin 
filament length (Pappas, Krieg, & Gregorio, 2010). 
Aside from actin, Tmod and Z-disc interactions, nebulin also interacts with a variety 
of other proteins that are involved in the myofibrillogenesis, organization of actin 
cytoskeleton, and stabilization of nebulin. Kelch-like proteins, KLHL40 (Garg et al., 
2014) and KLHL41 (unpublished data, Gupta Lab), have been shown to interact with 
nebulin, assisting in the stabilization of nebulin and promoting myofibril assembly. 
Desmin, an intermediate filament protein, binds to nebulin in the super repeat region, 
playing a role in spacing between adjacent actin filaments in the Z-disc, alignment of 
myofibrils and determination of actin filament length. Furthermore, the SRC Homology 3 
(SH3) domain of nebulin, located within the Z-disc, interacts with a variety of proteins 
that play roles in myofibril assembly and actin cytoskeleton organization (Figure 3). 
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Figure 3. Structure and Organization of Nebulin in Sarcomeres. In sarcomeres, the C-
terminus of nebulin is located in the Z-disk and the N-terminus is located near the pointed end of 
the thin filament. The SH3 domain binds with many proteins including myopalladin, titin and 
CapZ. Modules 163 through 170 connects the Z-disk region with the super repeat regions and 
contains the binding site for desmin and CapZ.  (Winter et al., 2013) 
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Proteasome Activators as Potential Therapy for Nemaline Myopathy 
 Proteasomes are important biological protein complexes involved in the selective 
degradation of intracellular proteins that have been marked for degradation by the 
substrate protein, ubiquitin. Ubiquitin marks a wide range of intracellular proteins, 
including regulatory proteins, which are broken down to their constituent amino acids by 
the 26S proteasome (Lecker, Goldberg, & Mitch, 2006). Therefore, this ubiquitin-
proteasome system (UPS) is necessary for a variety of cellular processes including stress 
signaling, proliferation of cells, cellular development, transcriptional regulation and DNA 
repair. A 26S or 30S proteasome consists of a core particle which is involved in the 
catalytic processes of protein degradation, and a regulatory particle, which serves to 
activate the core particle. In a 26S proteasome, the 20S proteasome is the core particle, 
while the 19S regulatory particle helps regulate the entry of ubiquitinated proteins to the 
20S subcomplex and activating degradation of this protein. The 20S proteasome has 
chymotrypsin-, trypsin-, and caspase-like activities, which cleaves peptide bonds located 
on the C-terminal side of hydrophobic, basic, and acidic amino acids, respectively, which 
make up three β-type subunits of the 2 inner β-rings. The 2 α-rings, located on the outside 
of the 20S proteasome acts as a channel to allow or prevent protein entry into the 
catalytic β-rings (Tanaka, 2009). 
 As previously mentioned, mutations in genes coding for several Kelch proteins 
are the cause of nemaline myopathy, including KLHL40, KLHL41, and KBTBD13 
(Malfatti et al., 2014). Studies have shown that Kelch proteins play a role in protein 
turnover particularly by interacting with Cul3 E3 ubiquitin ligases as substrate-specific 
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adaptors (Figure 4) (Zhang et al., 2005).  Unpublished data from Gupta lab has identified 
a downregulation of the proteasome complex in nemaline myopathy patients regardless 
of the genetic background (unpublished data, Gupta Lab) suggesting that restoration of 
proteasome complexes may result in normal muscle function in nemaline myopathy.  
 
 
Figure 4. KLHL41 Functions as Substrate-specific Adaptor for Cul3-based E3 Ubiquitin 
Ligases. Cul3 binds with KLHL41 by interacting with the BTB domain. Interaction between 
Kelch-repeat domains and substrates of the E3 ubiquitin ligase complex results in ubiquitination 
of protein targets. As a result, proteasomes will recognize and degrade ubiquitinated proteins. 
(Gupta & Beggs, 2014) 
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A number of small molecules have been identified to upregulate proteasome level 
or activity in mammalian cells (Huang & Chen, 2009; Myeku et al., 2016). One of such 
compounds include Oleuropein, a natural compound isolated from the leaf of the olive 
tree Olea europaea  that activates chymotrypsin-, trypsin-, and caspase-like activities in 
proteasomes by opening the channels on the α-ring, increasing the rate of peptide 
hydrolysis, of the 20S proteasome (Katsiki et al., 2007).  Sulforaphane, an indirect 
antioxidant, has also demonstrated proteasome activation properties by elevating 
transcriptional expression of the catalytic subunits of proteasomes, while increasing the 
chymotrypsin- and caspase-like activity of the proteasomes (Kwak et al., 2007). 
Mevalonolactone is a proteosomal agonist that has been described to increase the 
peptidase activity of proteasomes (Rao et al., 1999). Previous studies from our lab has 
demonstrated that sulforaphane improves motor function in neb zebrafish, suggesting that 
upregulation of proteasomes may play a significant role in the development of a viable 
treatment for nemaline myopathy patients (Unpublished data, Gupta Lab). In order to 
expand these studies to evaluate the effect of other proteasome activators our studies 
focused on the effects of two proteasome activators (betulinic acid and Rolipram) in 
nemaline myopathy. 
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Betulinic Acid 
 Betulinic acid is a pentacyclic triterpene (Figure 5) that is primarily isolated from 
the Betula species. It has been shown to possess anti-HIV (Aiken & Chen, 2005), anti-
inflammatory, antihelminthic, antimalarial, antibacterial and antitumor characteristics as 
well (Ali-Seyed et al., 2016).  
 
  
Figure 5. The Structure of Betulinic Acid. (Weber et al., 2014) 
 
Betulinic acid is a proteasome activator that activates the chymotrypsin-like 
activity of the 20S proteasome. Unlike PA28 and sodium dodecyl sulfate (SDS) which 
are proteasome activators commonly used in proteasome assays, betulinic acid is able to 
activate the 20S proteasome at low micromolar concentrations and does this in a dose 
dependent manner. PA28 and SDS have been shown to activate trypsin-, chymotrypsin-, 
and caspase-like activities of proteasomes by inducing conformational changes or 
partially denaturing the 20S proteasome, respectively, allowing substrate access to the 
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proteolytic site. However, betulinic acid only activates the chymotrypsin-like activity, 
demonstrating that betulinic acid activates proteasomes in a mode of action different from 
PA28 and SDS (Huang et al., 2007).  
 
Rolipram 
 Rolipram (Figure 6) is a phosphodiesterase IV (PDE IV) inhibitor, particularly 
inhibiting the PDE IVB subtype, which are involved in the hydrolysis of cAMP and 
cGMP in various organs, especially in nerve cells and immune cells. 
 
 
Figure 6. The Structure of Rolipram. (Pubchem, n.d.)  
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Previous studies have demonstrated in a mouse model of tauopathy that the 
presence of insoluble tau decreases chymotrypsin-, trypsin-, and caspase-like activities in 
26S proteasome. When this model was treated with Rolipram in early stages of the 
disease, cognitive abilities improved and the tauopathy was reduced. Rolipram achieves 
this by phosphorylating 26S proteasomes and enhancing the chymotrypsin-, trypsin-, and 
caspase-like activities in these proteasomes, which in turn improves UPS-mediated 
protein degradation. In tauopathy mouse models treated with Rolipram, no difference in 
the concentration of extracted proteasomes was observed, but the proteasome activity was 
increased to levels comparable to that of wild-type mice (Myeku et al., 2016).  
 
Utility of Zebrafish Models for Muscle Disease Studies 
 While many different model organisms exist currently within the biological 
research fields, zebrafish has been shown to be a great model for human muscle diseases 
(Maves, 2014). Zebrafish may act as an effective model for high throughput small 
molecular screening or drug treatments compared with murine models due to their ability 
to be produced in large numbers. Zebrafish primary myogenesis is completed in 48 hours 
post fertilization, making them an excellent model to study muscle development in short 
time spans. Zebrafish has also been used as a model for human muscle diseases as 
zebrafish and human share similar muscle structures and conserved disease genes. A 
number of approaches for zebrafish muscle analysis exists, making it easy and efficient to 
study the effects of different compounds and drugs on the zebrafish muscle disease 
models (Maves, 2014). One of these methods include the analysis of birefringence. When 
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positioned properly between two polarized lenses on a stereo microscope, unaffected 
zebrafish skeletal muscles will appear bright, while affected zebrafish skeletal muscles 
will show darkened disruptions or a reduction of the total birefringence (Smith, Beggs, & 
Gupta, 2013). Other methods of analysis includes the use of immunofluorescence 
staining, dyeing, immunocytochemistry, histology and electron microscope to provide 
information on the muscle fiber and sarcomere defects, and reveal muscle damage in 
zebrafish muscle disease models (Maves, 2014). 
 The Dowling lab has established a nemaline myopathy zebrafish model with a 
G>A mutation in exon 43, resulting in no nebulin protein production or a truncated 
nebulin missing the N-terminus. This zebrafish model recapitulated similar 
histopathological features that are observed in human nemaline myopathy patients. In 
particular, this zebrafish model has nemaline bodies in skeletal muscles, exhibits reduced 
muscle force generation, and length of skeletal muscle thin filaments, similar to the 
clinical and pathological features seen in nemaline myopathy patients (Telfer et al., 
2012). Zebrafish models with ACTA1 mutations have also been produced and exhibit  
similar pathological defects in skeletal muscle seen in human NM patients (Sztal et al., 
2015). Because nemaline myopathy causing genes are conserved in zebrafish and mutant 
fish exhibit similar clinical and pathological defects, these zebrafish models can be used 
for testing therapies for nemaline myopathy (Maves, 2014). Proteasome complexes are 
reduced in the different forms of NM. As NEB mutations underlie 40-50% of all 
nemaline myopathy cases, therefore evaluating the effect of proteasome activators in 
nebulin zebrafish will potentially benefit a large group of NM patients. Proteasome 
 16 
activators that improve muscle functions in neb zebrafish models can then be further 
evaluated for the efficiency in rarer subtypes of nemaline myopathy. 
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Specific Aims 
Nemaline myopathy is a genetically heterogeneous disease for which no therapies 
are available yet. Previous studies in our lab have demonstrated that proteasome 
complexes are downregulated in NM. Therefore, we hypothesize that by upregulating 
proteasomes levels, we may be able to restore muscle function in NM.   
The specific aims for this work are: 
1. To evaluate the effect of proteasomal activators (betulinic acid and Rolipram) on 
improvement of skeletal muscle structure and function in neb zebrafish model 
2. To gain insight on which proteasome activator makes the greatest improvement 
on skeletal muscle structure and function in neb zebrafish model 
Through this study, we aim to therapeutically modulate proteasomes in nemaline 
myopathy and identify potential therapeutics. Successful completion of this work will 
result in identification of therapeutics that may be used to target a wide array of muscle 
diseases. 
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METHODS 
Zebrafish Handling 
 All zebrafish handling has been carried out in accordance with the Institutional 
Animal Care and Use Committee (IACUC) approved guidelines and procedures.  
 
neb Zebrafish 
neb zebrafish (line sa906) were obtained from the Zebrafish International 
Resource Center (ZIRC, Eugene, OR). In order to generate a new generation of zebrafish 
heterozygous for the neb mutation, the zebrafish acquired from ZIRC were inbred and the 
embryos were maintained and raised. 
 
Genotyping and Selecting for Heterozygous neb zebrafish 
 To genotype neb fish, adult fish were anesthetized and fin tissue was taken from 
each fish. DNA was isolated by incubating the tissue in 25µL of alkaline lysis reagent 
(25mM NaOH and 0.2mM EDTA in water) at 96o C for 2 hours followed by 
neutralization by 25µL of buffer (40mM Tris-HCl, in water). PCR analysis of the 
zebrafish DNA samples was performed by using primers 5’-
CAAGGAAGGCACATTGCC-3’ (forward) and 5’-TCTGGACCTTTGAGGCGAT-3’ 
(reverse). The PCR was performed for 10 cycles (92o C for 30 seconds, 70o C for 30 
seconds, 68o C for 30 seconds), then 30 cycles (92o C for 30 seconds, 60o C for 30 
seconds, 68o C for 30 seconds) in 25 µL reactions of 1X PCR Buffer (Qiagen, KY), 2.5 
µM MgCl2 (Qiagen, KY), 200 µM each dNTP (Denville, MA), 0.1 µM of both forward 
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and reverse primers, 2.5 units Taq DNA Polymerase (Qiagen, KY), and 2 µL of DNA 
sample. 
 The PCR products were submitted for Sanger sequencing (performed at the 
Boston Children’s Hospital Molecular Genetics Core Facility, MA). We compared 
sample sequences obtained from Sanger sequencing with the reference sequence to detect 
neb mutation using Sequencher DNA Sequence Analysis Software (Gene Codes 
Corporation, MI) and heterozygous fish were raised to adulthood. neb carriers display 
one allele with a C>T point mutation at Chr 9: 23050917 (Figure 7). 
 
                * 
 
Figure 7. Point Mutation in neb Carriers. DNA sequencing of neb carrier adult zebrafish 
display one allele with a C>T point mutation at Chr 9: 23050917 (*), which results in a premature 
stop. (“ZFIN Feature: sa906,” n.d.) 
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Small Molecule Treatment of neb Zebrafish 
Heterozygous neb zebrafish were mated and embryos were collected at 0 hpf. At 
1 dpf, groups of 20 embryos were randomly chosen from the pool and transferred into a 
single well of 12-well plate (Corning Life Sciences, MA). DMSO (vehicle) (Sigma-
Aldrich, MO) or betulinic acid (Sigma-Aldrich, MO), were added to the 1X E3 media 
(5mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33mM MgSO4) and added to fish 
embryos. The numbers of embryos treated with different concentration of compounds are 
described below (Table 1). 
 
Table 1: Treatment Conditions with DMSO-only and Betulinic Acid 
Treatment Concentration Number of Treated 
Embryos 
DMSO 0.01% (v/v) 80 
DMSO 0.05% (v/v) 80 
DMSO 0.1% (v/v) 80 
Betulinic Acid 1 µg/mL 80 
Betulinic Acid 5 µg/mL 80 
Betulinic Acid 10 µg/mL 80 
Betulinic Acid 100 µg/mL 20 
 
At 4 dpf, the solution in each well was replaced with fresh betulinic acid or 
DMSO and dead embryos were removed periodically. Similar treatment was performed 
with Rolipram and numbers of embryos treated with different concentration of 
compounds are described below (Table 2). 
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Table 2: Treatment Conditions with DMSO-only and Rolipram  
Treatment Concentration Number of Treated 
Embryos 
DMSO 0.01% (v/v) 80 
DMSO 0.05% (v/v) 80 
DMSO 0.10% (v/v) 80 
Rolipram 1 µg/mL 80 
Rolipram 5 µg/mL 80 
Rolipram 10 µg/mL 80 
 
Zebrafish were checked daily at 2-7 dpf for deaths, which were removed upon 
observation. At 4 dpf, the solution in each well was replaced with fresh 1mL 1X E3 
media treated with DMSO only or Rolipram, which were maintained at the same 
concentration as the initial treatment from 1 dpf.  
 
Zebrafish Motor Analysis 
 At 7 dpf, zebrafish pools were separated  into individual wells in 1mL water in 
24-well plates (Corning Life Sciences, MA) (Tables 3&4). In order to determine the 
effects of betulinic acid or Rolipram on locomotor function in neb Zebrafish, Daniovision 
observation chamber (Noldus Information Technology, VA), an infrared tracking system 
designed for high-throughput tracking of zebrafish larvae locomotion, was used. The 
system setting was set up to maintain the water temperature at 28o C throughout the 
experiment. Using the EthoVision XT software (Noldus Information Technology, VA), 
each 24-well plate was exposed to 5 minutes of darkness, followed by 20 minutes of 
white light. For each fish, total swimming distance and time were recorded.  
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Table 3: Number of Larvae Observed when Treated with DMSO-only and Betulinic 
Acid  
 
Treatment Number of 24-well Plates Number of Larvae 
Observed 
DMSO 0.01% (v/v) 1 24 
DMSO 0.05% (v/v) 1 24 
DMSO 0.10% (v/v) 1 24 
Betulinic acid 1 µg/mL 2 48 
Betulinic acid 5 µg/mL 2 48 
Betulinic acid 10 µg/mL 2 48 
Betulinic acid 100 µg/mL 1 20 
 
 
 
Table 4: Number of Larvae Observed when Treated with DMSO-only and 
Rolipram 
 
Treatment Number of Larvae Observed 
DMSO 0.01% (v/v) 76 
DMSO 0.05% (v/v) 80 
DMSO 0.1% (v/v) 77 
Rolipram 1 µg/mL 47 
Rolipram 5 µg/mL 15 
Rolipram 10 µg/mL 46 
 
 
 
Birefringence Assay 
 The birefringence analysis was performed to identify structural changes in the 
sarcomere of the treated fish. Live zebrafish larvae were analyzed by polarized light at 
8dpf. The zebrafish was oriented on the lateral axis of its body and positioned so that the 
maximum birefringence of the fish could be seen.  For curved fish, the flattest portion of 
the zebrafish was used to determine the level of birefringence (Smith, Beggs, & Gupta, 
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2013). All images of wild-type and neb zebrafish were obtained using SteREO Discovery 
V8 stereo microscope equipped with AxioCam HR (Zeiss, Germany). 
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RESULTS 
Birefringence Analysis of neb Zebrafish 
 The zebrafish larvae were categorized as having normal or reduced birefringence. 
When observed between two polarized lenses, the neb zebrafish had disrupted or reduced 
birefringence. Wild-type zebrafish express normal birefringence that appears bright when 
oriented properly. 12.86% neb zebrafish express physiological defects including 
pericardial edema, but is not present in every zebrafish expressing reduced levels of 
birefringence (Figure 8). Neb zebrafish are homozygous for a point mutation (C>T) at 
Chromsome 9: 23050917, which results in the formation of a premature stop codon in 
nebulin. On the other hand, control zebrafish are heterozygous for the point mutation 
(C>T) or homozygous for wild-type nebulin. Neb zebrafish are observed to have a 
reduced locomotion compared with wild-type zebrafish when observed 7 dpf, which may 
be a result of the disorganized sarcomeric structure observed in zebrafish with reduced or 
disrupted birefringence.  
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Figure 8. neb Larvae Display Abnormal Birefringence. 4 dpf neb zebrafish were analyzed 
under polarized light. 12.86% neb larvae possess morphological defects such as pericardial edema 
(left panels). neb zebrafish display reduced birefringence compared with wild-type larvae (right 
panels).  
 
 
 
 
4 days post fertilization Birefringence 
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Treatment with Betulinic Acid  
 The effects of betulinic acid on the locomotion of neb zebrafish were investigated 
by treating neb zebrafish embryos at 1 dpf with 1 µg/mL, 5 µg/mL, 10 µg/mL, or 100 
µg/mL betulinic acid. At 7 dpf, the swimming distance of zebrafish in different 
concentrations of betulinic acid were recorded using the Daniovision observation 
chamber. A decline in distance swam by wild-type and neb zebrafish was observed in 
zebrafish analyzed in the evening compared with those analyzed during the day. 
Therefore, the distance swam by each fish was normalized to the longest distance swam 
in their respective 24-well plate. Within the treated and untreated population, zebrafish 
were further categorized based on normal or reduced birefringence (Appendix A). 
Furthermore, the mean normalized distance travelled by zebrafish were compared and 
statistical significance was tested using unpaired two-tailed student’s t-test. wild-type and 
neb zebrafish treated with betulinic acid were compared with wild-type and neb zebrafish 
treated with DMSO, respectively.  
 In this trial, treatment with 0.01%, 0.05%, and 0.10% DMSO resulted in mean 
normalized swimming distances of 0.44 (SD = 0.29), 0.55 (SD = 0.23), and 0.54 (SD = 
0.29) in wild-type zebrafish, respectively, and 0.059 (SD = 0.035), 0.039 (SD = 0.031), 
and 0.044 (SD = 0.010) in neb zebrafish, respectively. Wild-type zebrafish treated with 1 
µg/mL, 5 µg/mL, and 10 µg/mL betulinic acid showed mean normalized swimming 
distances of 0.50 (SD = 0.27), 0.48 (SD = 0.28), and 0.48 (SD = 0.24) in wild-type 
zebrafish, respectively, and 0.043 (SD = 0.027), 0.044 (SD = 0.026), and 0.041 (SD = 
0.027) in neb zebrafish, respectively (Table 5). No statistically significant changes were 
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observed in wild-type and neb zebrafish treated with 1 µg/mL, 5 µg/mL, and 10 µg/mL 
betulinic acid compared with those treated with 0.01%, 0.05%, and 0.10% DMSO, 
respectively (Figure 9). 
 
Table 5: Mean Normalized Swimming Distances of Wild-type and neb zebrafish 
Treated with Betulinic Acid 
 
 
Interestingly, there was a high percentage, specifically 42.36%, mutant zebrafish 
in the treated population and 57.64% wild-type. However, the untreated zebrafish 
consisted of 76.06% wild-type and 23.94% neb. We expect 25% of zebrafish analyzed to 
have the neb mutation and 75% to be wild-type. However, this observed increased in the 
percentage of neb zebrafish is likely due to random selection from the pool of embryos 
acquired from 8 clutches. 
 Zebrafish treated with 100 µg/mL betulinic acid displayed significant death at 6-7 
dpf. However, no significant deaths of zebrafish were observed in 1 µg/mL, 5 µg/mL, 
and 10 µg/mL betulinic acid treatments. This observation demonstrates that treatment of 
 Wild-type neb 
0.01% DMSO 0.44 (SD = 0.29) 0.059 (SD = 0.035) 
0.05% DMSO 0.55 (SD = 0.23) 0.039 (SD = 0.031) 
0.10% DMSO 0.54 (SD = 0.29) 0.044 (SD = 0.010) 
1 µg/mL betulinic acid 0.50 (SD = 0.27) 0.043 (SD = 0.027) 
5 µg/mL betulinic acid 0.48 (SD = 0.28) 0.044 (SD = 0.026) 
10 µg/mL betulinic acid 0.48 (SD = 0.24) 0.041 (SD = 0.027) 
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100 µg/mL betulinic acid is toxic to zebrafish compared with treatments with 1 µg/mL, 5 
µg/mL, and 10 µg/mL betulinic acid. 
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Figure 9. Treatment with Betulinic Acid Did Not Show Any Statistically Significant Effects 
on Mean Distance Traveled (Normalized to 1.0) in Wild-type and neb Zebrafish. Error bars, 
mean + 1 S.D.; (Unpaired two-tailed student’s t-test to determine significance in difference 
observed in mean distance travelled) 
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In the replicate trial, the same procedure was performed. The distance traveled by 
each fish was normalized to the longest distance traveled in their respective 24-well dish 
(Appendix B). The birefringence of each fish was analyzed and the mean normalized 
distance of each treatment was taken. Statistical analysis with unpaired two-tailed 
student’s t-test, assuming unequal variance, was conducted to compare between treated 
and untreated wild-type or neb zebrafish at the three tested concentrations. Similar results 
were obtained in the replicate trial (Figure 10). 
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Figure 10. Treatment with Betulinic Acid Shows Improvement in neb Zebrafish Motor 
Function at 5 µg/mL in Second Experimental Trial. Error bars, mean + 1 S.D.; *P < 0.05 
(Unpaired two-tailed student’s t-test to determine significance in difference observed in mean 
distance travelled) 
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Treatment with Rolipram 
 In order to determine the effects of Rolipram on zebrafish locomotor, wild-type 
and neb zebrafish embryos were treated 1 dpf with 1 µg/mL, 5 µg/mL, or 10 µg/mL 
Rolipram.  At 7 dpf, individual zebrafish were isolated into 24-well plates and the 
swimming distance of each fish was recorded with the Daniovision observation chamber. 
At 8 dpf, each zebrafish was categorized as wild-type or neb by level of birefringence. As 
performed with betulinic acid treatment, the distance travelled by each fish was 
normalized by the longest distance travelled in their respective 24-well plate (Appendix 
C). The statistical significance of the effects of the treatments on zebrafish were analyzed 
by conducting unpaired two-tailed student’s t-tests comparing the normalized mean 
distance traveled in treated and untreated wild-type or neb zebrafish at different 
concentrations.  
 Treatment with 0.01%, 0.05%, and 0.10% DMSO, the mean normalized 
swimming distance was 0.37 (SD = 0.29), 0.36 (SD = 0.21), and 0.49 (SD = 0.30) in 
wild-type zebrafish, respectively and 0.12 (SD = 0.13), 0.36 (SD = 0.21), and 0.096 (SD 
= 0.077), respectively. When treated with 1 µg/mL, 5 µg/mL, and 10 µg/mL Rolipram, 
the mean normalized swimming distance was 0.44 (SD = 0.26), 0.32 (SD = 0.30), and 
0.49 (SD = 0.30) in wild-type zebrafish, respectively, and 0.063 (SD = 0.10), 0.0046 (SD 
= 0.0061), and 0.089 (SD = 0.12), respectively (Table 6). Treatment with Rolipram did 
not display any trends that are indicative of a positive effect on neb zebrafish (Figure 11).  
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Table 6: Mean Normalized Swimming Distances of Wild-type and neb zebrafish 
Treated with Rolipram 
 
 
Untreated zebrafish consisted of 74.78% wild-type and 25.22% neb mutants, 
while treated zebrafish consisted of 70.65% wild-type and 29.35% neb mutants, which 
demonstrates that Rolipram did not affect the lifespan of neb zebrafish or decrease the 
percentage of neb zebrafish expressing reduced or disrupted birefringence when observed 
at 7 dpf. 
 Significant deaths were observed on 7 dpf in 1 µg/mL, 5 µg/mL, and 10 µg/mL 
Rolipram-treated zebrafish, which suggest that treatment with Rolipram is toxic to 
zebrafish; however, additional trials are needed to confirm this.  
 
 
 
 
 
 Wild-type neb 
0.01% DMSO 0.37 (SD = 0.29) 0.12 (SD = 0.13) 
0.05% DMSO 0.36 (SD = 0.21) 0.36 (SD = 0.21) 
0.10% DMSO 0.49 (SD = 0.30) 0.096 (SD = 0.077) 
1 µg/mL Rolipram 0.44 (SD = 0.26) 0.063 (SD = 0.10) 
5 µg/mL Rolipram 0.32 (SD = 0.30) 0.0046 (SD = 0.0061) 
10 µg/mL Rolipram 0.49 (SD = 0.30) 0.089 (SD = 0.12) 
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Figure 11. Treatment with Rolipram did not reveal any Significant Trends Indicative of 
Improved Motor Function in neb Zebrafish. Error bars, mean + 1 S.D.; *P < 0.01, ** P < 
0.001 (Unpaired two-tailed student’s t-test to determine significance in difference observed 
in mean distance travelled) 
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DISCUSSION 
  
Nemaline myopathy is a devastating muscular disorder due to the lack of effective 
treatments that could improve the quality of life of affected individuals or reduce the 
clinical severity of the disorder. Studies have shown that the majority of nemaline 
myopathy cases are a result of mutations in genes encoding thin filament proteins; 
however, studies have also shown that mutations in genes encoding Kelch-like proteins 
cause the disorder. Kelch protein, KLHL41, has been shown to interact with Cul3 E3 
ubiquitin ligases as substrate-specific adaptors, which regulate the protein turnover 
process in cells (Zhang et al., 2005). Preliminary data from our lab has demonstrated a 
decrease in KLHL41-proteasome complex in human nemaline myopathy patients, 
regardless of the genetic mutations associated with the disease (unpublished data, Gupta 
Lab). This demonstrates a potential target for therapy that may have an effect on 
nemaline myopathy patients. Previous studies in our lab have demonstrated that 
upregulating proteasome function in neb zebrafish improves motor function in neb 
zebrafish; however, betulinic acid, a 20S proteasome activator, and Rolipram, a 26S 
proteasome enhancer, had yet to be studied as potential therapeutics for nemaline 
myopathy.  We decided to study betulinic acid and Rolipram to evaluate their effects on 
neb zebrafish and compare the effectiveness of these proteasome activators with other 
proteasome activators on skeletal muscle function in neb zebrafish. Effective proteasome 
regulators that result in the improvement of skeletal muscle function in neb zebrafish can 
then be tested in zebrafish models with other subtypes of nemaline myopathy.  
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 Treatment with betulinic acid did not display any statistically significant 
improvements in neb zebrafish in the first trial. The replicate trial also confirms that 
betulinic acid treatment did not show significant improvement in neb zebrafish muscle 
function. Our findings from these trials also suggest that treatment with 100 µg/mL 
betulinic acid is toxic to zebrafish, which resulted in significant death observed at 6-7 dpf 
in both trials. 
In the first trial with betulinic acid, the 42.36% neb zebrafish expressing disrupted 
or reduced birefringence in the treated population was likely due to random selection 
from the pool of embryos collected from 8 clutches. The DMSO-treated population in the 
same trial was observed to have 23.94% neb zebrafish, which is close to the expected 
25%. In the second trial, 36.62% of the DMSO-treated population and 24.82% of the 
betulinic acid treated population of zebrafish expressed disrupted or reduced 
birefringence. This observation from the second trial further suggests that the observed 
increase in neb zebrafish was due to random selection and not due to the effects of 
betulinic acid on the zebrafish.  
 Treatments with Rolipram did not display trends indicative of a positive or 
negative effect on neb zebrafish skeletal muscle function. In our trial, significant 
zebrafish deaths were observed 7 dpf when treated with 1 µg/mL, 5 µg/mL, and 10 
µg/mL Rolipram, which suggest that the drug is toxic to zebrafish. These deaths reduced 
the number of neb zebrafish we could analyze at 7 dpf, which resulted in a lack of an 
observed trend in neb zebrafish when treated with Rolipram. Because the experimental 
trial with Rolipram was only conducted once, additional trials are required to confirm the 
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toxicity of Rolipram on zebrafish and determine the effects of Rolipram on neb zebrafish 
skeletal muscle function.  
 Preliminary data from our lab has suggested that upregulation of proteasome 
activity improves the motor function of neb zebrafish (unpublished data, Gupta Lab). 
However, this study did not find any effect of betulinic acid and Rolipram on 
improvement in neb function. The solubility, stability, and absorption of betulinic acid 
and Rolipram were not explored in this experiment, but may play a role in the lack of an 
effect seen in treated neb zebrafish using both proteasome regulators. 
One weakness of this study was the lack of multiple replicates to increase the 
robustness of these work. If future studies exhibit an improvement in motor function, 
experiments can be performed to determine the effects of betulinic acid and Rolipram on 
neb zebrafish skeletal muscles, including whole-mount immunofluorescence, electron 
microscopy, and skeletal muscle force generation analysis. Furthermore, if betulinic acid 
and Rolipram are shown to improve motor function in neb zebrafish significantly, then 
the drug-like compound should be tested in different subtypes of nemaline myopathy. 
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APPENDIX A 
 
 
Figure A1. Normalized Distance Traveled for Each Fish Treated with 1 µg/mL Betulinic 
Acid, First 24-well Plate. N, normalized birefringence; R, reduced birefringence. 
 
 
Figure A2. Normalized Distance Traveled for Each Fish Treated with 1 µg/mL Betulinic 
Acid, Second 24-well Plate. N, normalized birefringence; R, reduced birefringence. 
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Figure A3. Normalized Distance Traveled for Each Fish Treated with 5 µg/mL Betulinic 
Acid, First 24-well Plate. N, normalized birefringence; R, reduced birefringence. 
 
 
Figure A4. Normalized Distance Traveled for Each Fish Treated with 5 µg/mL Betulinic 
Acid, Second 24-well Plate. N, normalized birefringence; R, reduced birefringence. 
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Figure A5. Normalized Distance Traveled for Each Fish Treated with 10 µg/mL Betulinic 
Acid, First 24-well Plate. N, normalized birefringence; R, reduced birefringence. 
 
 
Figure A6. Normalized Distance Traveled for Each Fish Treated with 10 µg/mL Betulinic 
Acid, Second 24-well Plate. N, normalized birefringence; R, reduced birefringence. 
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Figure A7. Normalized Distance Traveled for Each Fish Treated with 100 µg/mL Betulinic 
Acid. Dead zebrafish were labeled 8 dpf during birefringence analysis, but were alive during 
mobility analysis at 7dpf. N, normalized birefringence; R, reduced birefringence. 
 
 
Figure A8. Normalized Distance Traveled for Each Fish Treated with 0.01% DMSO. N, 
normalized birefringence; R, reduced birefringence. 
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Figure A9. Normalized Distance Traveled for Each Fish Treated with 0.05% DMSO. N, 
normalized birefringence; R, reduced birefringence. 
 
 
Figure A10. Normalized Distance Traveled for Each Fish Treated with 0.10% DMSO. N, 
normalized birefringence; R, reduced birefringence. 
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APPENDIX B 
 
 
Figure B1. Normalized Distance Traveled for Each Fish Treated with 1 µg/mL Betulinic 
Acid, First 24-well Plate. Dead zebrafish were labeled 8 dpf during birefringence analysis, but 
were alive during mobility analysis at 7dpf. N, normalized birefringence; R, reduced 
birefringence. 
 
 
 
Figure B2. Normalized Distance Traveled for Each Fish Treated with 1 µg/mL Betulinic 
Acid, Second 24-well Plate. Dead zebrafish were labeled 8 dpf during birefringence analysis, but 
were alive during mobility analysis at 7dpf. N, normalized birefringence; R, reduced 
birefringence. 
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Figure B3. Normalized Distance Traveled for Each Fish Treated with 5 µg/mL Betulinic 
Acid, First 24-well Plate. N, normalized birefringence; R, reduced birefringence. 
 
 
Figure B4. Normalized Distance Traveled for Each Fish Treated with 5 µg/mL Betulinic 
Acid, Second 24-well Plate. N, normalized birefringence; R, reduced birefringence. 
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Figure B5. Normalized Distance Traveled for Each Fish Treated with 10 µg/mL Betulinic 
Acid, First 24-well Plate. N, normalized birefringence; R, reduced birefringence. 
 
 
Figure B6. Normalized Distance Traveled for Each Fish Treated with 10 µg/mL Betulinic 
Acid, Second 24-well Plate. Dead zebrafish were labeled 8 dpf during birefringence analysis, but 
were alive during mobility analysis at 7dpf. N, normalized birefringence; R, reduced 
birefringence. 
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Figure B7. Normalized Distance Traveled for Each Fish Treated with 100 µg/mL Betulinic 
Acid. Dead zebrafish were labeled 8 dpf during birefringence analysis, but were alive during 
mobility analysis at 7dpf. N, normalized birefringence; R, reduced birefringence. 
 
 
Figure B8. Normalized Distance Traveled for Each Fish Treated with 0.01% DMSO. Dead 
zebrafish were labeled 8 dpf during birefringence analysis, but were alive during mobility 
analysis at 7dpf. N, normalized birefringence; R, reduced birefringence. 
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Figure B9. Normalized Distance Traveled for Each Fish Treated with 0.05% DMSO. N, 
normalized birefringence; R, reduced birefringence. 
 
 
Figure B10. Normalized Distance Traveled for Each Fish Treated with 0.10% DMSO. N, 
normalized birefringence; R, reduced birefringence. 
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APPENDIX C 
 
 
Figure C1. Normalized Distance Traveled for Each Fish Treated with 1 µg/mL Rolipram, 
First 24-well Plate. Dead zebrafish were labeled 8 dpf during birefringence analysis, but were 
alive during mobility analysis at 7dpf. N, normalized birefringence; R, reduced birefringence. 
 
 
Figure C2. Normalized Distance Traveled for Each Fish Treated with 1 µg/mL Rolipram, 
Second 24-well Plate. Dead zebrafish were labeled 8 dpf during birefringence analysis, but were 
alive during mobility analysis at 7dpf. N, normalized birefringence; R, reduced birefringence. 
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Figure C3. Normalized Distance Traveled for Each Fish Treated with 5 µg/mL or 10 µg/mL 
Rolipram. Normalized distance traveled for zebrafish treated with 5 µg/mL Rolipram are 
displayed on the left of the divider line, while those of zebrafish treated with 10 µg/mL Rolipram 
are displayed on the right of the divider line. Dead zebrafish were labeled 8 dpf during 
birefringence analysis, but were alive during mobility analysis at 7dpf. N, normalized 
birefringence; R, reduced birefringence. 
 
 
Figure C4. Normalized Distance Traveled for Each Fish Treated with 10 µg/mL Rolipram. 
Dead zebrafish were labeled 8 dpf during birefringence analysis, but were alive during mobility 
analysis at 7dpf. N, normalized birefringence; R, reduced birefringence. 
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Figure C5. Normalized Distance Traveled for Each Fish Treated with 10 µg/mL Rolipram 
or 0.01% DMSO. Normalized distance traveled for zebrafish treated with 10 µg/mL Rolipram 
are displayed on the left of the divider line, while those of zebrafish treated with 0.01% DMSO 
are displayed on the right of the divider line. Dead zebrafish were labeled 8 dpf during 
birefringence analysis, but were alive during mobility analysis at 7dpf. N, normalized 
birefringence; R, reduced birefringence. 
 
 
Figure C6. Normalized Distance Traveled for Each Fish Treated with 0.01% DMSO, 
Second 24-well Plate. Dead zebrafish were labeled 8 dpf during birefringence analysis, but were 
alive during mobility analysis at 7dpf. N, normalized birefringence; R, reduced birefringence. 
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Figure C7. Normalized Distance Traveled for Each Fish Treated with 0.01% DMSO, Third 
24-well Plate. N, normalized birefringence; R, reduced birefringence. 
 
 
Figure C8. Normalized Distance Traveled for Each Fish Treated with 0.01% or 0.05% 
DMSO. Normalized distance traveled for zebrafish treated with 0.01% DMSO are displayed on 
the left of the divider line, while those of zebrafish treated with 0.05% DMSO are displayed on 
the right of the divider line. Dead zebrafish were labeled 8 dpf during birefringence analysis, but 
were alive during mobility analysis at 7dpf. N, normalized birefringence; R, reduced 
birefringence. 
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Figure C9. Normalized Distance Traveled for Each Fish Treated with 0.05% DMSO, 
Second 24-well Plate. Dead zebrafish were labeled 8 dpf during birefringence analysis, but were 
alive during mobility analysis at 7dpf. N, normalized birefringence; R, reduced birefringence. 
 
 
Figure C10. Normalized Distance Traveled for Each Fish Treated with 0.05% DMSO, 
Third 24-well Plate. Dead zebrafish were labeled 8 dpf during birefringence analysis, but were 
alive during mobility analysis at 7dpf. N, normalized birefringence; R, reduced birefringence. 
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Figure C12. Normalized Distance Traveled for Each Fish Treated with 0.05% DMSO, 
Fourth 24-well Plate. N, normalized birefringence; R, reduced birefringence. 
 
 
Figure C12. Normalized Distance Traveled for Each Fish Treated with 0.05% or 0.10% 
DMSO. Normalized distance traveled for zebrafish treated with 0.05% DMSO are displayed on 
the left of the divider line, while those of zebrafish treated with 0.10% DMSO are displayed on 
the right of the divider line. N, normalized birefringence; R, reduced birefringence. 
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Figure C13. Normalized Distance Traveled for Each Fish Treated with 0.10% DMSO, 
Second 24-well Plate. Dead zebrafish were labeled 8 dpf during birefringence analysis, but were 
alive during mobility analysis at 7dpf. N, normalized birefringence; R, reduced birefringence. 
 
 
Figure C14. Normalized Distance Traveled for Each Fish Treated with 0.01% DMSO, 
Third 24-well Plate. Dead zebrafish were labeled 8 dpf during birefringence analysis, but were 
alive during mobility analysis at 7dpf. N, normalized birefringence; R, reduced birefringence. 
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Figure C15. Normalized Distance Traveled for Each Fish Treated with 0.10% DMSO, 
Fourth 24-well Plate. Dead zebrafish were labeled 8 dpf during birefringence analysis, but were 
alive during mobility analysis at 7dpf. N, normalized birefringence; R, reduced birefringence. 
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